BlackRock, Inc. filed an amended Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of 3,871,884 shares of Zentalis Pharmaceuticals Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported beneficial ownership of 3,871,884 shares of Zentalis Pharmaceuticals Inc. common stock.
  • Percent of class: The reported stake represents 4.1% of the outstanding common shares of Zentalis Pharmaceuticals Inc.
  • Sole voting power: BlackRock disclosed sole power to vote or direct the vote of 3,797,590 shares.
  • Sole dispositive power: BlackRock disclosed sole power to dispose or direct the disposition of 3,871,884 shares.
  • Shared voting and dispositive power: Both shared voting power and shared dispositive power are reported as 0.
  • Date of event: The filing is based on holdings as of September 30, 2026.
  • Reporting person type: BlackRock, Inc. is classified as a holding company (HC), organized in Delaware, with its principal business office at 50 Hudson Yards, New York, NY 10001.

BlackRock's Amended 13G Ownership Position in Zentalis Pharmaceuticals

BlackRock, Inc. filed Amendment No. 1 to its Schedule 13G regarding its holdings in Zentalis Pharmaceuticals Inc. (CUSIP: 98943L107), whose principal executive offices are located at 10275 Science Center Drive, Suite 200, San Diego, CA 92121. According to the filing, the event requiring this statement occurred on September 30, 2026, and the document was signed by Spencer Fleming, Managing Director of BlackRock, on October 27, 2026.

The filing discloses that BlackRock beneficially owns 3,871,884 shares of Zentalis Pharmaceuticals common stock, representing 4.1% of the class. Of these, BlackRock holds sole voting power over 3,797,590 shares and sole dispositive power over the full 3,871,884 shares. Shared voting and shared dispositive power are each listed as 0. The filing checks the box under Item 5 confirming ownership of 5 percent or less of a class.

The filing notes, in accordance with SEC Release No. 34-39538, that the Schedule 13G "reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates." It further states that the filing does not include securities, if any, beneficially owned by other business units whose beneficial ownership is disaggregated from that of the Reporting Business Units. Regarding Item 6, the filing states that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Zentalis Pharmaceuticals Inc.," and confirms that no single person's interest exceeds five percent of total outstanding common shares.

What Was Disclosed

BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of 3,871,884 shares, or 4.1%, of Zentalis Pharmaceuticals Inc. common stock as of September 30, 2026, with sole voting power over 3,797,590 shares and sole dispositive power over all reported shares.